跳到正文
原文
MedPage Today·· 4 天前精选AI 评分85

FDA 批准 obinutuzumab 用于治疗原发性膜性肾病

FDA OKs First Drug for Primary Membranous Nephropathy

AI 导读

FDA 批准 obinutuzumab 用于治疗原发性膜性肾病,该药在 MAJESTY 试验中显示了优于 tacrolimus 的蛋白尿缓解效果。这是首个获批用于该疾病的药物。

推荐理由

FDA 批准 obinutuzumab 用于治疗原发性膜性肾病,填补了该领域的空白。

正文

— Anti-CD20 antibody obinutuzumab lands indication on strength of MAJESTY trial

by Ian Ingram, Managing Editor, MedPage Today

November 16, 2026 • 2 min read

The FDA has once again expanded the label for the B-cell depleter obinutuzumab (Gazyva), this time to include treatment of primary membranous nephropathy.

The new indication, announced by the agency on Friday, stipulates use of the anti-CD20 monoclonal antibody to induce remissions of proteinuria in adults at risk for progression from primary membranous nephropathy. It marks the first approved agent for the type of autoimmune kidney disease where off-label options had become standard.

"Primary membranous nephropathy is a rare kidney disease caused by immune system attack on the glomeruli, which are the tiny filters in the kidneys that clean waste products from the blood," the FDA stated. "The glomeruli become inflamed and damaged, leaking large amounts of protein into the urine. Patients can develop high cholesterol, high blood pressure, severe swelling, fatigue, kidney failure, and other complications."

Phase III trial data from MAJESTY underpinned the approval, showing superior proteinuria remission rates with obinutuzumab versus tacrolimus, an immunosuppressive drug used off-label for the disease.

In the open-label trial, 37% of the patients assigned to obinutuzumab achieved a complete remission at 2 years -- defined as a urinary protein-to-creatinine ratio of ≤0.3 amid a stable estimated glomerular filtration rate -- versus just 6% of those on tacrolimus (P<0.001).

The percentage of patients with either a complete or partial remission was also higher in the obinutuzumab group (51% vs 13%, P<0.001), and benefits appeared consistent across prespecified subgroups.

Common side effects with obinutuzumab in the trial included infusion-related reactions (38%) and upper respiratory tract infections (14%).

Primary membranous nephropathy has typically been managed with off-label drugs, including agents that block the renin-angiotensin-aldosterone system, immunosuppressive agents, glucocorticoids, cytotoxic medications, and calcineurin inhibitors. Rituximab, a first-generation anti-CD20 antibody, has also shown benefit.

In patients without diabetes, the autoimmune kidney disease is the leading cause of idiopathic nephrotic syndrome.

Obinutuzumab now carries three indications in kidney disease, following approvals earlier this year for childhood-onset idiopathic nephrotic syndrome and last year for active lupus nephritis, based on results of the REGENCY study. The biologic is also approved for chronic lymphocytic leukemia and follicular lymphoma, while systemic lupus erythematosus may be its next indication.

The label for obinutuzumab carries boxed warnings for hepatitis B virus reactivation and progressive multifocal leukoencephalopathy. The warnings and precautions section also notes potential risks for infusion-related reactions, hypersensitivity reactions, serious infections (live-virus vaccines should be avoided while using the drug), neutropenia and thrombocytopenia, disseminated intravascular coagulation, and embryo-fetal toxicity.

来源:MedPage Today · medpagetoday.com